Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow the first two Wegovy doses compare in practice: tolerability, appetite effects and what the evidence says
You've just opened your first Wegovy pen, here's what 0.25mg is actually for
Picture the scene: the pen's in the fridge, you've read the leaflet twice, and you're wondering why the starting dose feels almost symbolic. That's because it is, in the best possible way. The 0.25mg weekly dose exists purely to let your body adjust to semaglutide, the GLP-1 receptor agonist in Wegovy that slows gastric emptying and signals fullness to the brain. If you're curious about how semaglutide and Wegovy relate to each other as a medicine and a brand, that page explains the distinction clearly. At this level, meaningful appetite suppression is limited for most people. Nausea, the side effect that stops many from continuing, tends to be much milder when the medicine is introduced gradually.
A quick habit worth building from day one: note the date of each injection on your phone calendar. That single check (thirty seconds, done) makes it far easier to track when your four weeks at 0.25mg are up and to have a clear conversation with your prescriber about moving forward. The Wegovy treatment overview covers what to expect across the full schedule.
Clinically, 0.25mg isn't assessed for weight-loss effect. The NHS medicines page for semaglutide is clear that the initial dose is a starter, with gradual titration the intended path. Side effects at this stage, when they appear, are mostly mild gastrointestinal: some queasiness, occasional loose stools, or a reduced desire to finish a plate. Most people find they settle within the first week or two.
What changes when you step up to 0.5mg
At 0.5mg (typically from week five onward, subject to how you've tolerated the first month) the pharmacological effect becomes more noticeable. Appetite suppression is more consistent, food noise quiets down for many people, and the sense of satiety after smaller portions begins to feel more reliable. This is also the point where side effects can tick back up briefly, for the same reason they arrived at 0.25mg: the dose is new to your system again.
The key things that change between the two doses: the depth of GLP-1 receptor activation increases, gastric emptying slows more, and the hormonal signals that tell your brain meals are over arrive sooner. What doesn't change is the injection schedule, still once weekly, same sites (abdomen, thigh or upper arm), rotated each time. Storage requirements stay the same too; for the exact room-temperature window, the Wegovy SmPC on the eMC is the definitive reference.
The STEP 1 trial, published in the New England Journal of Medicine, found that semaglutide at 2.4mg produced around 15% average weight reduction over 68 weeks. Neither 0.25mg nor 0.5mg is the destination, both are early steps on a titration ladder that climbs toward that maintenance dose, and now potentially toward the newly approved 7.2mg option for eligible patients.
A side-by-side look at 0.25mg and 0.5mg
The table below compares the two doses factually across the dimensions most people ask about.
| Feature | Wegovy 0.25mg | Wegovy 0.5mg |
|---|---|---|
| Primary purpose | Tolerability/initiation | Continued titration toward maintenance |
| Typical duration | ~4 weeks | ~4 weeks (then assessed for next step) |
| Weight-loss effect | Minimal at this dose | Beginning to emerge for many people |
| GI side-effect risk | Generally low; system adjusting | May briefly increase after step-up |
| Injection frequency | Once weekly | Once weekly |
| Storage | Refrigerated (2–8°C); see SmPC for room-temp window | Refrigerated (2–8°C); same rules apply |
Numbers in this table reflect the licensed titration schedule; individual experience varies. A prescriber decides whether to hold, step up, or adjust based on your response. For a broader sense of how Wegovy sits alongside other treatment options, the comparison of GLP-1 medicines is a useful read.
What your prescriber is watching for before moving you up
The step from 0.25mg to 0.5mg isn't automatic. A clinician reviews whether side effects have been manageable, whether you've been able to inject consistently, and whether there are any early signs of concern (gallbladder symptoms, severe or persistent stomach pain that radiates toward the back, seek urgent help if that occurs, as the MHRA's guidance on GLP-1 medicines flags pancreatitis as a known risk requiring prompt assessment). That review exists to protect you, not to slow you down unnecessarily.
This is why a service with genuine clinical oversight matters at this stage. At nume, a GPhC-registered prescriber (not an algorithm) reviews repeat requests and dose-change evidence before anything is approved or dispatched. Questions about how that process works are answered on our FAQs page, and if you'd prefer to talk it through, our team is reachable via the contact page.
One thing worth noting: Ozempic is also semaglutide but it is licensed for type 2 diabetes, not weight management, and if you want to understand how Wegovy and Ozempic differ despite sharing the same active ingredient, that page sets out the distinction clearly. For cost context, the guide to Wegovy pricing in the UK covers what private treatment typically costs and what that price should include.
Which dose suits you, and at what pace, is a clinical decision our prescribers make with you, and if you're weighing up how Wegovy compares to other weight-loss treatments before committing, that overview is worth reading first. Speak to our prescribers through a free consultation, the same day, no waiting list.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.